The efficacy of MGBL action on PARP-1 in vitro and in vivo suggests that MGBLs can be a starting point for developing novel drugs against PARP-1 to treat malignant tumors sensitive to PARP-1 inhibition. The gene discussed is PARP1; the disease is cancer.